<\/p>\n
PharmaNutra S.p.A. keeps on growing and consolidating in Italy and abroad, as preliminary consolidated revenue figures for the first half of 2020<\/strong> show*.<\/p>\n <\/p>\n In the first six months of 2020, the PharmaNutra Group recorded consolidated revenue for about \u20ac29\u00a0<\/strong>million<\/strong>, compared to 25 million in the same period last year, with a +17% compared to the first half of\u00a0<\/strong>2019<\/strong>. The total, detailed results will be circulated after the Board of Directors\u2019 meeting called to approve the interim financial statements on 14th September 2020.<\/p>\n <\/p>\n Despite operating difficulties connected to the Covid-19 pandemic, the Group never stopped, <\/p>\n The positive market results, where the SiderAL\u00ae<\/sup> line products and those of the Cetilar\u00ae<\/sup> line have gained and maintained market shares exceeding the trends of their respective reference sectors (\u201ciron supplements\u201d and \u201ctopical\u201d market), also translate into a continuing climb for PharmaNutra in the\u00a0<\/strong>ranking of nutraceutical sector companies<\/strong>, drawn up every year by IQVIA, world leader and point of reference in processing and analysing healthcare data. In the ranking of more than 1700 nutraceutical companies in the Italian classification, calculated based on sales to the public, PharmaNutra went from 15th to 12th place<\/strong> in 2019.<\/p>\n <\/p>\n Andrea Lacorte, President of PharmaNutra S.p.A., commented<\/strong>: \u201cPharmaNutra works looking to the future considering the global economic scenario that Covid-19 will be bringing us. The company never stopped and thanks to its innovative digital projects in augmented reality, managed to continually communicate with doctors and pharmacists with no problems even during the lockdown period. An aspect that enabled us to achieve important results from a scientific and a sales point of view, even in the worst part of the emergency. We will keep on expanding internationally and widening the range of products sold, not just through distribution agreements but also considering setting up subsidiaries in some Countries. We expect 2020 to be a positive year too where, net of the lockdown period absorption, the Group will grow considerably, supported by its capital solidity\u201d.<\/em><\/p>\n <\/p>\n * Data not yet audited.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":" PharmaNutra also climbs the annual IQVIA ranking in number of products sold, coming twelfth out of more than 1700 Italian […]<\/p>\n","protected":false},"author":7,"featured_media":9107,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[129],"tags":[],"class_list":["post-11370","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-corporate-en","anno_documento-16"],"yoast_head":"\n
\novercoming the limits imposed on medical information activities using new tools and methods. In the
\nfirst six months of 2020, finished product sales volumes grew 32% compared to the first half of 2019\u00a0<\/strong>thanks to a significant contribution from foreign markets where, since the start of the year, the Group has signed seven new agreements in Asia, Latin America and Europe.<\/p>\n